Fact checked byChristine Klimanskis, ELS

Read more

January 22, 2024
1 min read
Save

Sandoz to acquire ranibizumab biosimilar from Coherus

Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Cimerli is a ranibizumab biosimilar.
  • Sandoz will pay $170 million in cash for the biosimilar.

Sandoz has signed an agreement to acquire ranibizumab biosimilar Cimerli from Coherus BioSciences, according to a press release.

The $170 million cash deal includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software.

Generic Breaking News infographic
Sandoz has signed an agreement to acquire ranibizumab biosimilar Cimerli from Coherus BioSciences, according to a press release.

Sandoz said the deal will allow it to build a more robust ophthalmic platform that could support future product launches.

“I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise,” Sandoz North America president Keren Haruvi said in the release. “The addition of Cimerli reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the U.S.”

The acquisition of Cimerli (ranibizumab-eqrn) is expected to close in the first half of the year.